
Sofinnova leads €11m fundraising for DNA Script
Leading shareholder Sofinnova and a host of new and existing investors have taken part in an €11m funding round for French company DNA Script.
Existing investors Sofinnova, Kurma and Idinvest were joined by Illumina Ventures and Merck Ventures in the series-A.
The funds raised will allow DNA Script to strengthen its enzymatic technology and nucleotide chemistry platform in order to manufacture oligonucleotides in a faster, cleaner and more affordable way compared with current market standards.
Sofinnova now holds 10 industrial biotech companies after launching a new strategy to target the sector in 2009. It invests in the space through its €22.5m Green Seed fund and its €106m Sofinnova IB I fund.
Company
Founded in 2014 in Paris, DNA Script manufactures synthetic nucleic acids using enzymatic technology. According to the company, its technology has the potential to be used in the development of new therapeutics, sustainable chemical production, improved crops and data storage.
People
Sofinnova Partners – Joško Bobanović (partner).
DNA Script – Thomas Ybert (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater